Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We…
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We…
Neuphoria Therapeutics signed a definitive merger agreement with Scancell under which each Neuphoria share will convert into Scancell ADSs plus one CVR, targeting post-close ownership of about 11.1% for Neuphoria holders. Closing is subject to shareholder approvals, Nasdaq listing of Scancell ADSs…
RNS Number : 5640N Scancell Holdings Plc 23 July 2026 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF EU REGULATION NO. 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). UPON THE PUBLICATION…
